Table 2 Availability of anti-malarial drugs and malaria rapid diagnostic tests in private outlets
Total | Healthcare providers | Retailers | p value** | ||||||
|---|---|---|---|---|---|---|---|---|---|
Private facility | Health worker | Total | Pharmacy | Itinerant drug vendor | General retailer | Total | |||
N (%) | 1,159 | 194 (17%) | 218 (19%) | 412 (36%) | 342 (29%) | 136 (12%) | 269 (23%) | 747 (64%) | |
Availability of anti-malarial | |||||||||
Quality assured ACT† | 280 (24%) | 93 (48%) | 156 (72%) | 249 (60%) | 10 (3%) | 11 (8%) | 10 (4%) | 31 (4%) | <0.001 |
Non-artemisinin drugs | 677 (58%) | 118 (61%) | 140 (64%) | 258 (62%) | 168 (49%) | 113 (83%) | 138 (51%) | 419 (56%) | <0.05 |
Injectable artemisinin-based monotherapy | 341 (29%) | 76 (39%) | 59 (27%) | 135 (33%) | 153 (45%) | 33 (24%) | 20 (7%) | 206 (28%) | <0.001 |
Oral artemisinin-based monotherapy | 677 (58%) | 83 (43%) | 44 (20%) | 127 (31%) | 304 (89%) | 39 (29%) | 207 (77%) | 550 (74%) | <0.001 |
Non QA-ACT | 67 (6%) | 24 (12%) | 2 (1%) | 26 (6%) | 38 (11%) | 1 (1%) | 2 (1%) | 41 (6%) | <0.05 |
Availability of RDT | 293 (25%) | 99 (51%) | 157 (72%) | 256 (62%) | 20 (6%) | 12 (9%) | 5 (2%) | 37 (5%) | <0.001 |